Product Overview
[Drug Name]
Generic Name: Irbesartan Tablets
Trade Name: Geping
English Name: Irbesartan Tablets
Chinese Pinyin: Ebeishatan Pian
[Ingredients]
The main ingredient of this product is irbesartan, whose chemical name is 2-butyl-3-[4-[2-(1H-tetrazol-5-yl)phenyl]benzyl]-1,3-diazaspiro-[4,4]non-1-en-4-one.
[Properties]
This product is white tablets or film-coated tablets.
[Indications]
Hypertension.
[Dosage and Administration]
Oral: The recommended starting dose is 0.15g once daily. Depending on the condition, it can be increased to 0.3g once daily. It can be used alone or in combination with other antihypertensive drugs. For severe hypertension or when blood pressure remains unsatisfactory after increasing the dose, a small dose of a diuretic (such as a thiazide) or other antihypertensive drug can be added.
[Adverse Reactions]
Common adverse reactions include headache, dizziness, palpitations, and occasional cough. These reactions are generally mild and transient, and most patients tolerate continued medication well. Urticaria and angioedema are rare. Literature reports of adverse reactions with an incidence greater than 1% for this drug include: dyspepsia, heartburn, diarrhea, musculoskeletal pain, fatigue, and upper respiratory tract infection, but these reactions were not significantly different from the control group. Other adverse reactions reported with an incidence greater than 1% but lower than the control group include abdominal pain, anxiety, nervousness, chest pain, pharyngitis, nausea and vomiting, rash, and tachycardia. The incidence of hypotension and orthostatic hypotension is approximately 0.4%.
[Contraindications]
This drug is contraindicated in patients with allergies.
[Precautions]
1. Correct any hypovolemia and/or sodium deficiency before initiating treatment. 2. Patients with renal insufficiency may require a reduced dose of this drug. In addition, monitor changes in blood urea nitrogen, serum creatinine, and potassium. As a result of renin-angiotensin-aldosterone inhibition, some sensitive patients may experience changes in renal function. 3. No dose adjustment is required for patients with hepatic impairment or the elderly. 4. Irbesartan is not excreted through hemodialysis.
[Special Population Use]
Precautions for Children:
No safety data are available for patients under 18 years of age.
Precautions for Pregnancy and Lactation:
This drug is contraindicated in pregnant and lactating women.
Precautions for the Elderly:
Although a starting dose of 75 mg may be considered for patients over 75 years of age, no dose adjustment is generally required for elderly patients.
[Drug Interactions]
1. When using this drug with diuretics, be aware of hypovolemia or hyponatremia, which may cause hypotension. When used with potassium-sparing diuretics (such as triamterene), avoid increasing serum potassium. 2. There are no significant interactions between this drug and warfarin. 3. Co-administration with digitalis drugs such as digoxin, beta-blockers such as atenolol, and calcium antagonists such as nifedipine does not affect the pharmacokinetics of these drugs.
[Pharmacological Action]
This product is an angiotensin II (Ang II) receptor inhibitor, inhibiting the conversion of Ang I to Ang II. It specifically antagonizes the angiotensin-converting enzyme 1 receptor (AT1), with an antagonistic effect on AT1 being 8500 times greater than that on AT2. By selectively blocking the binding of Ang II to the AT1 receptor, it inhibits vasoconstriction and aldosterone release, resulting in a hypotensive effect. This product does not inhibit angiotensin-converting enzyme (ACE), renin, or other hormone receptors, nor does it inhibit ion channels involved in blood pressure regulation and sodium homeostasis.
[Storage] Store in a sealed container.
[Specification] 0.15g
[Packaging] Double aluminum packaging, 10 tablets per plate, 1 plate per box.
[Expiry Date] 36 months. Approval Number: National Medicine Standard H20053912
Manufacturer: Xiuzhen Pharmaceutical Group Co., Ltd.
